Vericel Corporation (VCEL)
Stock Price:
$15.74 USD
0.57 (3.76%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
707.72M |
| Revenue (ttm) |
122.72M |
| Net Income (ttm) |
-3,000 |
| Shares Out |
45.11M |
| EPS (ttm) |
0.00 |
| PE Ratio |
n/a |
| Forward PE |
500.00 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$15.74 |
| Previous Close |
$15.17 |
| Change ($) |
0.57 |
| Change (%) |
3.76% |
| Day's Open |
15.20 |
| Day's Range |
14.94 - 15.85 |
| Day's Volume |
630,264 |
| 52-Week Range |
6.78 - 19.57 |
More Stats
| Market Cap |
707.72M |
| Enterprise Value |
653.29M |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
45.11M |
| Float |
35.70M |
| EPS (basic) |
0.02 |
| EPS (diluted) |
0.00 |
| FCF / Share |
0.22 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
1.43% |
| Payout Ratio |
n/a |
| Shares Short |
6.47M |
| Short Ratio |
9.07 |
| Short % of Float |
14.09% |
| Beta |
2.96 |
| PE Ratio |
n/a |
| Forward PE |
500.00 |
| P/FCF Ratio |
69.87 |
| PS Ratio |
5.77 |
| PB Ratio |
6.50 |
| Revenue |
122.72M |
| Operating Income |
-1.13M |
| Net Income |
-3,000 |
| Free Cash Flow |
10.13M |
| Net Cash |
54.43M |
| Net Cash / Share |
1.21 |
| Gross Margin |
65.42% |
| Operating Margin |
-0.92% |
| Profit Margin |
n/a |
| FCF Margin |
8.25% |
| ROA |
-5.56% |
| ROE |
-10.80% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$23.40*
(48.67% upside)
Low
20.0
Current: $15.74
High
32.0
Target: 23.40
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 118 | 90.86 | 63.92 | 54.38 | 51.17 | 28.80 | 0.02 | 0.02 | 0.02 | 0.09 |
| Revenue Growth | 29.71% | 42.13% | 17.54% | 6.28% | 77.69% | 151457.89% | -9.52% | 16.67% | -79.78% | - |
| Gross Profit | 80.28 | 58.70 | 33.57 | 26.08 | 24.70 | 11.50 | 0.02 | 0.02 | 0.01 | 0.06 |
| Operating Income | -11.25 | -3.91 | -14.98 | -19.25 | -16.67 | -23.53 | -20.96 | -33.76 | -29.04 | -17.80 |
| Net Income | -9.67 | -8.14 | -17.29 | -19.57 | -16.34 | -19.92 | -15.62 | -29.47 | -19.67 | -14.56 |
| Shares Outstanding | 44.18 | 40.24 | 33.36 | 23.09 | 23.76 | 11.64 | 3.02 | 2.06 | 1.93 | 1.24 |
| Earnings Per Share | -0.22 | -0.20 | -0.52 | -1.18 | -0.97 | -2.23 | -6.95 | -16.25 | -10.18 | -11.80 |
| Operating Cash Flow | -7.18 | -0.41 | -13.18 | -19.89 | -13.35 | -25.41 | -19.94 | -29.55 | -24.49 | -15.09 |
| Capital Expenditures | -2.62 | -2.68 | -1.51 | -1.42 | -2.43 | -0.83 | -0.04 | -0.27 | -1.03 | -0.12 |
| Free Cash Flow | -9.80 | -3.09 | -14.69 | -21.31 | -15.77 | -26.24 | -19.98 | -29.82 | -25.52 | -15.21 |
| Cash & Equivalents | 69.81 | 82.92 | 26.86 | 22.98 | 14.58 | 30.34 | 8.06 | 13.64 | 5.53 | 19.12 |
| Total Debt | 27.70 | - | 17.24 | 10.13 | 0.07 | 0.11 | - | 0.04 | 0.08 | 0.31 |
| Net Cash / Debt | 42.10 | 82.92 | 9.62 | 12.85 | 14.51 | 30.23 | 8.06 | 13.60 | 5.45 | 18.81 |
| Assets | 153 | 119 | 54.58 | 48.60 | 34.31 | 47.58 | 9.22 | 15.18 | 7.74 | 20.53 |
| Liabilities | 42.15 | 16.46 | 32.04 | 23.89 | 12.18 | 11.94 | 5.32 | 5.67 | 20.71 | 5.75 |
| Book Value | 111 | 102 | 22.54 | 24.71 | 22.13 | 35.64 | 3.89 | -32.10 | -12.97 | 14.78 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Vericel Corporation |
| Country |
United States |
| Employees |
241 |
| CEO |
Dominick C. Colangelo |
Stock Information
| Ticker Symbol |
VCEL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: VCEL |
| IPO Date |
February 4, 1997 |
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to dilated cardiomyopathy. In addition, its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.